{"nctId":"NCT00689611","briefTitle":"Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial","startDateStruct":{"date":"2005-12"},"conditions":["Acute Coronary Syndrome","Myocardial Infarction","Smoking"],"count":392,"armGroups":[{"label":"P","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bupropion HCl ER"]}],"interventions":[{"name":"Bupropion HCl ER","otherNames":["Zyban"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ≥ 18 years of age\n* Smoke at least 10 cigarettes/day for the past year\n* Suffered an enzyme-positive ACS\n* Planned hospitalization of ≥24 hours\n* Motivated to quit smoking\n* Likely to be available for follow-up\n* Able to understand and read English or French\n\nExclusion Criteria:\n\n* Medical condition with a prognosis of \\< 1 year\n* Pregnant or lactating\n* Current use of Wellbutrin or any other medications that contain bupropion\n* Current use of any medical therapy for smoking cessation (e.g. BuSpar, fluoxetine, doxepin, nicotine gum, or nicotine patch)\n* Current seizure disorder, history of seizures or predisposition to seizures (e.g. history of brain tumor, severe head trauma, or stroke)\n* History of bulimia or anorexia nervosa\n* Current diagnosis of major depression (requiring medication), bipolar disease, or dementia\n* History of suicidal events (previous suicide attempt, suicidal ideation) or family history of suicide\n* Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment (AST or ALT levels ≥ 2 times upper limit of normal prior to admission for ACS)\n* Renal impairment with creatinine levels ≥ 2 times the upper limit of normal\n* Excessive alcohol consumption defined as ≥ 14 alcoholic drinks per week\n* Use of any illegal drugs in the past year (e.g. cocaine, heroin, opiates)\n* Current use of medications that lower seizure threshold e.g. amantadine, anti-depressants, anti-malarials, anti-psychotics, levodopa, lithium, quinolone antibiotics, ritonavir, systemic steroids, theophyllin, type 1C antiarrhythmics (e.g. encainide, flecainide, propafenone)\n* Use of MAO inhibitors or thioridazine in the past 15 days\n* Current use of over-the-counter stimulants (e.g. ephedrine, phenylephrine) or anoretics","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Smoking Abstinence","description":"The primary end point was 7-day point prevalence smoking abstinence at 12 months. Smoking cessation was defined as self-reported abstinence in the week before the 12-month clinic visit and a measurement of exhaled carbon monoxide less than 11 ppm.\n\nThe primary end point was analyzed on an intention-to-treat (ITT) basis. Our ITT analysis assumed that those who withdrew consent or were lost to follow-up had returned to smoking at their baseline rates. This assumption is common in smoking cessation trials.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":null},{"groupId":"OG001","value":"37.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Major Adverse Cardiovascular Events (MACE)","description":"All clinical end points were adjudicated by members of the Endpoints Evaluation Committee who were blinded to treatment assignment.\n\nComposite MACE (death, myocardial infarction, unstable angina)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null},{"groupId":"OG001","value":"13.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":37,"n":200},"commonTop":["Insomnia","Dry mouth","Dizziness","Dysgeusia","Constipation"]}}}